Abstracts tagged "autoimmune diseases"

Abstract Number: 0828 • ACR Convergence 2022
Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease
Navneet Kaur¹, Xianhong Xie², Anna Korogodina³, Krystal L. Cleven⁴, Bibi Ayesha⁵ and Anand Kumthekar⁶, ¹Touro University Medical Group, Sacramento, CA, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Department of Medicine, Montefiore Medical Center-Wakefield/Albert Einstein College of Medicine, Bronx, NY, ⁴Division of Pulmonary Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Tarrytown, NY, ⁶Division of Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue disease (CTD). The aim of our study…
Abstract Number: 1111 • ACR Convergence 2022
Sarcoidosis Rates in BCG-Vaccinated and Unvaccinated Young Adults: A Danish Register-Based Study
Matthew Baker¹, Emese Vágó², Suzanne Tamang³, Erzsébet Horváth-Puhó² and Henrik Sørensen², ¹Stanford University, Stanford, CA, ²Aarhus University Hospital, Aarhus, Denmark, ³Stanford Center for Population Health Sciences, Redwood City, CA
Background/Purpose: The inciting factor or antigen exposure that initiates sarcoidosis remains unknown. However, an infectious trigger such as Mycobacterium spp. or Propionibacterium acnes infection may…
Abstract Number: 1274 • ACR Convergence 2022
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Elena Joerns¹, Nagendra Pokala², Dan Wang³, Joan Reisch³, Reuben Arasaratnam³, Bonnie Bermas¹ and Puneet Bajaj³, ¹UT Southwestern, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatology patients are at risk for severe pneumococcal infections due to their underlying disease and immunosuppressive therapy. Current Advisory Committee on Immunization Practices guidelines…
Abstract Number: 1523 • ACR Convergence 2022
Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease Are Associated with Systemic Sclerosis Skin Involvement
Darya S. Jalaledin¹, Hajar El Kamouni², Alexandra Albert³, Sabrina Hoa⁴, Josiane Bourre-Tessier⁵, Eric Rich⁵, Jean-Richard Goulet⁶, Martial Koenig⁷, Minoru Satoh⁸, Marvin Fritzler⁹, May Choi¹⁰, Yves Troyanov¹¹, Jean-Luc Senécal, MD¹² and Océane Landon-Cardinal⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Sherbrooke, Saint-Lambert, Canada, ²Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Laval, Canada, ³Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada, ⁴University of Montreal, Montréal, QC, Canada, ⁵Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Saint-Lambert, Canada, ⁷Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸Department of Human, Information and Science, University of Occupational Environmental Health, Kitakyusyu Fukuoka, Japan, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ¹¹Division of Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ¹²Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, Canada
Background/Purpose: RNA-binding region containing 3 (RNPC3) protein acts as a molecular bridge, promoting U11/U12 RNP complex formation. In previous studies, systemic sclerosis (SSc) patients who…
Abstract Number: 1738 • ACR Convergence 2022
Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases
Alexandra Khmelevskaya¹, Miranda Houtman², Kristina Buerki³, Chantal Pauli⁴, Sam Edalat³, Mojca Frank-Bertoncelj³, Oliver Distler⁵, Adrian Ciurea⁶, Caroline Ospelt⁷ and Raphael Micheroli⁸, ¹Center of Experimental Rheumatology, University Hospital of Zurich, Zürich, Switzerland, ²University of Zurich, Schlieren, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁴Department of Pathology, University Hospital Zurich, Zürich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁸University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), peripheral spondyloarthritis (pSpA), and undifferentiated arthritis (UA) are chronic immune-mediated conditions characterized by joint inflammation. The specific role…
Abstract Number: 2030 • ACR Convergence 2022
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
Jonathan Hubbard¹, Kim Campbell¹, Kathy Sivils¹, Robert Hoffman¹, Kim Hung Lo¹, Jocelyn Leu¹, Sophia Liva¹, Qing Zuraw¹, Anne Stevens¹, Leona Ling², Keith Karcher³, Sindhu Ramchandren³, Hong Sun³, Hal Scofield⁴, Daniel Wallace⁵ and Raphaèle Seror⁶, ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Cambridge, MA, ³Janssen Research & Development, LLC, Titusville, NJ, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
Abstract Number: 2272 • ACR Convergence 2022
Temporal Trends in COVID-19 Outcomes Among Patients with Systemic Autoimmune Rheumatic Diseases: From the First Wave to Omicron
Yumeko Kawano¹, Naomi Patel², Xiaosong Wang¹, Claire Cook³, Kathleen Vanni¹, Emily Kowalski¹, Emily Banasiak¹, Grace Qian¹, Michael Diiorio¹, Tiffany Hsu¹, Michael Weinblatt⁴, Derrick Todd¹, Zachary Wallace³ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Sale Creek, TN, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Advances in prevention, testing, and treatment of COVID-19 have contributed to less severe outcomes in the general population, but whether outcomes have improved for…
Abstract Number: 0124 • ACR Convergence 2022
Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Elena Joerns¹, Michelle Ghebranious¹, Traci Adams¹ and Una Makris², ¹UT Southwestern, Dallas, TX, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) which manifests with interstitial pneumonia and features of autoimmunity, yet…
Abstract Number: 0271 • ACR Convergence 2022
Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A Nationwide Population-based Study
Brinda Basida¹, maryam haider¹, Noren Din² and Vinit Gilvaz³, ¹DMC/Sinai Grace Hospital, Detroit, MI, ²DMC/Sinai- Grace Hospital, Birmingham, AL, ³Brown University, East Providence, RI
Background/Purpose: There has been an increasing global prevalence of celiac diseases (CD) and rheumatoid arthritis (RA). Modifications in proteins play a significant role in the…
Abstract Number: 0594 • ACR Convergence 2022
Identification of Peptidylglycine Alpha-Amidating Monooxygenase as a Regulator of Tissue Damage Mediated by Rheumatoid Arthritis Synovial Fibroblasts
Kevin Sheridan¹, Emma Dorris¹, Christopher Buckley² and Anthony Wilson¹, ¹University College Dublin, Dublin, Ireland, ²University of Oxford, Oxford, United Kingdom
Background/Purpose: The minor C allele variant of rs26232 SNP, located within the first intron of the Macrophage Immunometabolism regulator (MACIR) gene, is associated with both…
Abstract Number: 0708 • ACR Convergence 2022
The Impact of Early Antimalarial Adherence on Future Acute Care Utilization Among Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: To examine the association between antimalarial (AM) adherence and acute care utilization among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods:…
Abstract Number: 0764 • ACR Convergence 2022
No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors
Tawnie Braaten¹, Brian Sauer², Gary Kunkel³, Jessica Walsh³, Jorge Rojas⁴, Bryant England⁵, Joshua Baker⁶ and Grant Cannon⁷, ¹University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake City, UT, ⁴George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁷Salt Lake City VA, Salt Lake city
Background/Purpose: Immune checkpoint inhibitor (ICI) use for the treatment of multiple cancers continues to expand. Data on ICI treatment in autoimmune disease is limited as…
Abstract Number: 0831 • ACR Convergence 2022
Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital
Kinza Muzaffar¹, Sulman Hasan², Sarwat umer², Mohammad Alfrad Nobel Bhuiyan², Kavya Vadlamudi², Manush Sondhi², Anusheh Ali¹, Tabitha Muutu² and Samina Hayat¹, ¹Louisiana State University, Shreveport, LA, ²LSU Health Shreveport, Shreveport, LA
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease which can affect the GI system in about 5-10% of cases, out of which 11-80% can have hepatic…
Abstract Number: 1114 • ACR Convergence 2022
Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis
Dillon Popovich¹, Noelle Kosarek², Rezvan Parvizi³, Tamar Abel⁴, Mengqi Huang⁵, Monica Espinoza⁶, Avi Smith⁷, Sasha Shenk⁷, Jonathan Garlick⁷ and Michael Whitfield⁸, ¹Dartmouth College, West Lebanon, NH, ²Dartmouth Geisel School of Medicine, Lebanon, NH, ³Dartmouth, Lebanon, NH, ⁴Dartmouth College, Lebanon, NH, ⁵University of Pittsburgh, Pittsburgh, PN, ⁶Dartmouth College, Hanover, NH, ⁷Tufts University School of Dental Medicine, Boston, MA, ⁸Geisel School of Medicine, Lebanon, NH
Background/Purpose: Genome-wide analyses of gene expression in systemic sclerosis (SSc) skin biopsies have identified differential responses based on the mechanism of action of the therapy.…
Abstract Number: 1287 • ACR Convergence 2022
Are the American College of Rheumatology’s Web-Based Patient Education Materials Easy for Patients to Read and Comprehend?
Ugochukwu C Nweke¹, Sobia Hassan², Usama Ahmad³ and Meenakshi Jolly⁴, ¹Rush University,Graduate College, Chicago, IL, ²Rush University Medical Center, Chicago,IL, Chicago, IL, ³Rush Univesity Medical Center, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Patient education materials (PEMs), obtainable from online resources, can be accessed by patients and physicians and used to supplement the medical information provided by…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].